Published in Heart Fail Rev on January 01, 2004
Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction | NCT00576121
The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol (2009) 2.80
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
Intramyocardial fibroblast myocyte communication. Circ Res (2010) 1.98
MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol (2007) 1.78
Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem (2008) 1.47
Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics (2010) 1.42
Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol (2009) 1.31
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol (2005) 1.30
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity. J Biol Inorg Chem (2005) 1.17
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail (2007) 1.16
Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal (2011) 1.09
Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction. Mol Cell Biol (2006) 1.04
Intracardiac renin-angiotensin system and myocardial repair/remodeling following infarction. J Mol Cell Cardiol (2009) 1.01
Matrix metalloproteinases and myocardial infarction. Can J Cardiol (2007) 1.01
Blockade of NF-kappaB using IkappaB alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice. J Mol Biol (2008) 1.00
The giant danio (D. aequipinnatus) as a model of cardiac remodeling and regeneration. Anat Rec (Hoboken) (2011) 0.94
CD36 Is a Matrix Metalloproteinase-9 Substrate That Stimulates Neutrophil Apoptosis and Removal During Cardiac Remodeling. Circ Cardiovasc Genet (2015) 0.85
Renal studies provide an insight into cardiac extracellular matrix remodeling during health and disease. J Mol Cell Cardiol (2009) 0.84
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Bone marrow-derived CXCR4+ cells mobilized by macrophage colony-stimulating factor participate in the reduction of infarct area and improvement of cardiac remodeling after myocardial infarction in mice. Am J Pathol (2007) 0.83
Surgical approaches to left ventricular reconstruction: a matter of perspective. Heart Fail Rev (2013) 0.82
ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J Mol Cell Cardiol (2007) 0.82
Reduced expression of Cx43 attenuates ventricular remodeling after myocardial infarction via impaired TGF-beta signaling. Am J Physiol Heart Circ Physiol (2009) 0.80
A conceptual cellular interaction model of left ventricular remodelling post-MI: dynamic network with exit-entry competition strategy. BMC Syst Biol (2010) 0.80
Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice. PLoS One (2011) 0.80
Hemodialysis removes uremic toxins that alter the biological actions of endothelial cells. PLoS One (2012) 0.80
Dynamic interactions between the cellular components of the heart and the extracellular matrix. Pflugers Arch (2011) 0.79
A murine model of alcoholic cardiomyopathy: a role for zinc and metallothionein in fibrosis. Am J Pathol (2005) 0.79
Investigating chelating sulfonamides and their use in metalloproteinase inhibitors. Dalton Trans (2012) 0.78
Effects of doxycycline on cx43 distribution and cardiac arrhythmia susceptibility of rats after myocardial infarction. Iran J Pharm Res (2014) 0.76
Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function. J Cardiovasc Pharmacol (2009) 0.76
Angiotensinase C mRNA and Protein Downregulations Are Involved in Ethanol-Deteriorated Left Ventricular Systolic Dysfunction in Spontaneously Hypertensive Rats. Biomed Res Int (2015) 0.75
Methanethiol Binding Strengths and Deprotonation Energies in Zn(II)-Imidazole Complexes from M05-2X and MP2 Theories: Coordination Number and Geometry Influences Relevant to Zinc Enzymes. J Phys Chem B (2015) 0.75
Arrhythmogenic properties of dismantling cadherin-mediated adhesion in murine hearts. J Biomed Res (2010) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
The inflammatory response in myocardial infarction. Cardiovasc Res (2002) 7.92
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation (1987) 7.14
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res (2002) 6.37
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest (2000) 4.90
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A (1990) 4.46
Molecular mechanisms of myocardial remodeling. Physiol Rev (1999) 4.27
Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci (2002) 4.23
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol (1997) 4.09
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest (1999) 3.35
Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation (2001) 3.15
Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol (2001) 3.00
Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res (2002) 2.98
The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell (2001) 2.97
Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation (2003) 2.89
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 2.71
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell (2000) 2.49
Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature (1995) 2.40
Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst (2001) 2.24
Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol (2000) 2.21
Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol (1998) 2.19
Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 2.18
Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol (1994) 2.12
Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem (2001) 2.12
The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol (1997) 2.07
Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol (1995) 2.07
Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett (1998) 2.05
Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem (1989) 2.05
Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res (2002) 1.98
Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem (1996) 1.98
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol (1998) 1.87
Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res (2002) 1.83
Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation (2001) 1.81
Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol (1998) 1.75
Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem (1997) 1.75
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res (2002) 1.73
Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor. J Mol Cell Cardiol (2002) 1.68
Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation (2002) 1.67
Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol (1998) 1.65
The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells (1997) 1.65
Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem (1996) 1.64
Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation (1997) 1.62
TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem (1998) 1.59
Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation (2001) 1.59
Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. Circ Res (1999) 1.58
Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res (2000) 1.54
Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem (2001) 1.54
Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem (2002) 1.49
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer (2002) 1.49
The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol (1999) 1.48
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
Structure and biological activity of the extracellular matrix. J Mol Med (Berl) (1998) 1.45
TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine (1997) 1.42
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation (2002) 1.41
Complex role of matrix metalloproteinases in angiogenesis. Cell Res (1998) 1.37
Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett (1997) 1.36
Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation (1993) 1.34
Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest (2000) 1.33
Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem (1994) 1.32
Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation (2002) 1.30
Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem (2000) 1.29
Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J (1998) 1.29
Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest (1994) 1.28
Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J (2001) 1.25
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol (1994) 1.21
Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem (1993) 1.20
Insights into MMP-TIMP interactions. Ann N Y Acad Sci (1999) 1.18
Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain (2000) 1.18
Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem (1998) 1.17
p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem (1999) 1.15
Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation (1998) 1.14
Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol (2002) 1.14
The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. J Biol Chem (1998) 1.13
Differential effects of transforming growth factor-beta 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Exp Gerontol (1996) 1.10
Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol (2002) 1.10
Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res (1996) 1.10
Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res (2000) 1.09
Synthesis and release of procollagenase by cultured fibroblasts. J Biol Chem (1976) 1.09
Circulating interleukin-6 in severe heart failure. Am J Cardiol (1997) 1.07
Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells. Oncogene (1998) 1.06
Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci (2001) 1.06
Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol (2000) 1.06
Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. J Invest Dermatol (1996) 1.04
Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem (1997) 1.03
Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry (1998) 1.02
MMPs and TIMPs--an historical perspective. Mol Biotechnol (2002) 1.01
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail (2002) 1.01
Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem Biophys Res Commun (1999) 1.00
Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation (1990) 1.00
Echocardiography-derived left ventricular end-systolic regional wall stress and matrix remodeling after experimental myocardial infarction. J Am Coll Cardiol (1999) 1.00